- Teva Pharmaceutical press release (NYSE:TEVA): Q1 Non-GAAP EPS of $0.52.
- Revenue of $3.89B (+1.8% Y/Y).
- Underlying full-year outlook increased, excluding the impact of the Japan BV divestiture which closed on March 31, 2025 full year 2025 business outlook revised:
- Revenues
Teva Pharmaceutical guides FY revenue below consensus
